Breaking the Cost Barrier in Gene Therapy Manufacturing: Rethinking COGs to Enable Sustainable Commercialization
- Discussing why COGs, not efficacy, may be the greatest barrier to gene therapy adoption
- Sharing lessons from current commercial products: what the numbers really tell us about cost, pricing, and scalability
- Identifying high-impact levers for cost reduction across upstream, downstream, and release processes
- Bridging innovation and economics: what types of investment and collaboration are needed to enable sustainable manufacturing